BPC-157 Doses, As the Studies Record Them

How doses are expressed in the research literature

BPC-157 dosage in the published record is almost always expressed the way preclinical pharmacology expresses it: per kilogram of animal body weight, not as a fixed human amount. Rodent studies commonly use figures around 10 microg/kg and 10 ng/kg, and some tendon work goes as low as 10 pg per rat ^[1]. The gastric-ulcer cytoprotection studies used 400 ng/kg and 800 ng/kg in rats ^[4]. These are coordinates from animal experiments. They are recorded here to document what was administered in which study, and they are explicitly not a recommendation, a protocol, or human guidance.

The reason this distinction is not pedantic is that no validated human dose exists. The reader who wants a number to act on will not find one in the literature, because the studies that would establish one have not been run.

The few human pilot figures, in context

Human dose figures exist only as isolated coordinates from the three small pilot studies, and they are recorded here strictly as study facts. The first-in-human intravenous safety pilot used 10 mg on day one and 20 mg on day two, each by one-hour infusion, in two healthy adults ^[8]. A separate interstitial-cystitis pilot used 10 mg intravesically ^[8]. These milligram figures are not comparable to the per-kilogram microgram-to-nanogram animal doses above — they come from different routes, different purposes, and a different stage of evidence, and a safety pilot's dose is chosen to probe tolerability, not to define an effective amount.

No bridge exists between the animal figures and a human regimen. Allometric scaling from rodent per-kilogram doses is not validated for this peptide, the human pilots were not designed to find an effective dose, and no dose-finding human trial has been published ^[14]. The literature therefore supports describing what was given in each study and supports nothing about what amount a person should use.

The routes studied

BPC-157 has been administered by an unusually wide range of routes across the literature, which reflects how broadly it has been tested rather than any settled clinical practice. The most common route in rodent work is intraperitoneal; intramuscular, intragastric/peroral, and local intra-lesional delivery are also frequent. In the gastric-ulcer model, intramuscular delivery outperformed intragastric ^[4].

The three human pilot studies each used a different route: intravenous in the safety pilot, intravesical (into the bladder) in an interstitial-cystitis pilot, and intra-articular in a knee-pain case series ^[8]. This route diversity is one more reason the human picture is hard to read — there is no single route on which even a small body of consistent human evidence has accumulated. Storage and reconstitution practices reported by researchers are laboratory handling conventions, not validated clinical protocols.

Oral and peroral administration in the literature

Oral BPC-157 is studied because of one structural property: the peptide is termed a "stable gastric pentadecapeptide," reported to resist breakdown in human gastric juice ^[2]. Rodent studies have used peroral and intragastric dosing and reported effects by those routes, including in the foundational gastric-ulcer work ^[4].

Whether oral BPC-157 "works" in humans is, on the present evidence, unestablished. Resisting gastric breakdown is a precondition for oral activity, not a demonstration of it, and formal human oral pharmacokinetics have never been characterized ^[2]. The literature supports the narrower claim — the molecule is gastric-stable and has produced effects by oral routes in animals — and stops there.

Elimination half-life and pharmacokinetics

Any reading of BPC-157 dosage has to be set against its clearance. The 2022 PK/ADME study in rats and dogs found an elimination half-life under 30 min, linear pharmacokinetics, and intramuscular bioavailability of roughly 14-19% (rats) and 45-51% (dogs), with breakdown into small peptide fragments entering normal amino-acid metabolism ^[2]. A substance that clears in minutes but produces healing measured over weeks is, by that arithmetic, acting as a trigger rather than a persistent agent — which is the single most important thing the pharmacokinetic coordinate tells you, and the reason fixed human "cycles" cannot be derived from this record. The full BPC-157 half-life and pharmacokinetics discussion, including the bioavailability figures and metabolic fate, sits on the research page.